Primary plasma cell leukemia: A surveillance, epidemiology, and end results database analysis between 1973 and 2004

Cancer

Volumn 115, Issue 24, 2009, Pages 5734-5739

  Ramsingh, Giridharan ^a   Mehan, Paul ^a   Luo, Jingqin ^a   Vij, Ravi ^a   Morgensztern, Daniel ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

End results program; Epidemiology; Multiple myeloma; Plasma cell leukemia; Risk factors; Surveillance; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; DATA BASE; DISEASE SPECIFIC SURVIVAL; EPIDEMIC; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 73149083975     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24700     Document Type: Article

References (20)

1. International Myeloma Working Group.Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
2. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044-1052.
3. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25:1993-1999.
4. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
5. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521-2526.
6. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037.
7. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97:822-825.
8. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83:1062-1068.
9. Woodruff RK, Malpas JS, Paxton AM, Lister TA. Plasma cell leukemia (PCL): a report on 15 patients. Blood. 1978;52:839-845.
10. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. Br J Haematol. 1994;88:754-759.
11. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Codes for primary site and histology type. Cancer Surveillance, Epidemiology, and End Results reporting, October 1975. Available at: http://seer.cancer.gov/manuals/historic/ps-hist-1975.pdf. Accessed on January 10, 2009.
12. Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K. esponse of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res. 2008;32:1153-1156.
13. Benson DM Jr, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma. 2007;48:1423-1425.
14. Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007;109:2285-2290.
15. Finnegan DP, Kettle P, Drake M, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma. 2006;47:1670-1673.
16. Petrucci MT, Martini V, Levi A, et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma. 2007;48:180-182.
17. Wohrer S, Ackermann J, Baldia C, et al. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report. Hematol J. 2004;5:361-363.
18. Tsiara S, Chaidos A, Kapsali H, Tzouvara E, Bourantas KL. Thalidomide administration for the treatment of resistant plasma cell leukemia. Acta Haematol. 2003;109:153-155.
19. Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005;78:288-294.
20. Drake MB, Iacobelli S, van Biezen A, et al. Primary plasma cell leukaemia and autologous stem cell transplantation [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:731. Available at: http://abstracts. hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/731. Accessed on January 10, 2009.